Abstract | INTRODUCTION: METHODS: Sixty patients with acute gouty arthritis were randomised (1 : 1) to receive compound betamethasone 7 mg i.m. once for all during the study or diclofenac sodium 75 mg twice a day for 7 days in this open-label study. Pain intensity, tenderness, swelling and global assessment of response to therapy were collected as end-points for the treatment. RESULTS: The mean change in pain intensity from baseline to Day 3 and Day 7 in both treatment groups demonstrated that compound betamethasone had preferable efficacy over diclofenac sodium on Day 3 and comparable efficacy on Day 7. The compound betamethasone group had fewer adverse effects (AEs) than diclofenac sodium group. No statistically significant differences were observed about serum uric acid levels at different pain intensity at baseline. CONCLUSIONS:
|
Authors | Y-K Zhang, H Yang, J-Y Zhang, L-J Song, Y-C Fan |
Journal | International journal of clinical practice
(Int J Clin Pract)
Vol. 68
Issue 5
Pg. 633-8
(May 2014)
ISSN: 1742-1241 [Electronic] India |
PMID | 24472084
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2014 John Wiley & Sons Ltd. |
Chemical References |
- Gout Suppressants
- Diclofenac
- Betamethasone
|
Topics |
- Acute Disease
- Administration, Oral
- Betamethasone
(administration & dosage, adverse effects, therapeutic use)
- Diclofenac
(administration & dosage, adverse effects, therapeutic use)
- Female
- Gout
(drug therapy)
- Gout Suppressants
(administration & dosage, adverse effects, therapeutic use)
- Humans
- Injections, Intramuscular
- Male
- Middle Aged
|